Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection

NCT01147107 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C, Chronic
HIV Infection

Interventions

DRUG: Raltegravir
DRUG: Efavirenz

Sponsor

University of Hawaii

Collaborators

[object Object]
[object Object]
[object Object]